Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo‐controlled, double‐blind phase I/Ib studies in healthy subjects and patients

RIPK1 is a master regulator of inflammatory signaling and cell death and increased RIPK1 activity is observed in human diseases, including Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). RIPK1 inhibition has been shown to protect against cell death in a range of preclinical cellula...

Descripción completa

Detalles Bibliográficos
Autores principales: Vissers, Maurits F. J. M., Heuberger, Jules A. A. C., Groeneveld, Geert Jan, Oude Nijhuis, Jerome, De Deyn, Peter Paul, Hadi, Salah, Harris, Jeffrey, Tsai, Richard M., Cruz‐Herranz, Andres, Huang, Fen, Tong, Vincent, Erickson, Rebecca, Zhu, Yuda, Scearce‐Levie, Kimberly, Hsiao‐Nakamoto, Jennifer, Tang, Xinyan, Chang, Megan, Fox, Brian M., Estrada, Anthony A., Pomponio, Robert J., Alonso‐Alonso, Miguel, Zilberstein, Moshe, Atassi, Nazem, Troyer, Matthew D., Ho, Carole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372423/
https://www.ncbi.nlm.nih.gov/pubmed/35649245
http://dx.doi.org/10.1111/cts.13317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372423/
https://www.ncbi.nlm.nih.gov/pubmed/35649245
http://dx.doi.org/10.1111/cts.13317

Ejemplares similares